Cancer Vaccine Institute News

The Cancer Vaccine Institute (CVI) is proud to share our 2025 Year in Review that highlights our research and achievements. We made remarkable progress last year, advancing vaccines in clinical trials, moving vaccines in our preclinical pipeline forward, and sharing our research with the community. We are especially grateful to our patients, scientists, clinicians, collaborators, staff, faculty, and supporters. Your ongoing partnership and scientific leadership accelerates re

The Cancer Vaccine Institute (CVI) took park in the 2025 San Antonio Breast Cancer Symposium from December 9-12, 2025, bringing our latest research to one of the world's leading forums for breast cancer science. Faculty members from the CVI presented four scientific posters with fellow collaborators, researchers, and scientists. Through these presentations, the CVI team highlighted recent discoveries in HER2-targeted vaccines, neoadjuvant immunotherapy, and findings from our

Dr. Ying Liu presented this study at the 2025 San Antonio Breast Cancer Symposium At the UW Cancer Vaccine Institute, we are working to develop vaccines that train the immune system to recognize and eliminate cancer. At the 2025 San Antonio Breast Cancer Symposium, we shared new data comparing two of our HER2-targeted therapeutic vaccine platforms for people with advanced HER2-positive breast cancer. About 20% of all breast cancers overexpress the HER2 protein, which can make

The Cancer Vaccine Institute (CVI) was excited to share new results from a multi-center clinical trial led by Moffitt Cancer Center at the 2025 San Antonio Breast Cancer Symposium. These results offer encouraging evidence for WOKVAC, a HER2-targeted DNA vaccine developed here at the CVI. In this study, Moffitt and collaborating sites evaluated whether HER2 vaccination could help prevent recurrence in patients at especially high risk, including individuals who still have invas

At the 2025 San Antonio Breast Cancer Symposium, the UW Cancer Vaccine Institute shared new research revealing how a unique population of immune cells, shaped in part by the gut microbiome, may influence breast cancer growth and treatment response. Our team’s findings shed light on these immune cells called BAC‑TA T cells, their presence in newly diagnosed patients, and how precision probiotics could one day help shift the immune environment to better fight tumors. Dr. Denise